Trial Profile

Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Triphendiol (Primary)
Indications Solid tumours
Focus Adverse reactions; Pharmacokinetics
Sponsors Kazia Therapeutics; MEI Pharma; Novogen

Most Recent Events

17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
26 May 2008 New trial record.
15 May 2008 Results will be reported at the 44th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com